68Ga标记整合素αvβ6靶向环肽放射性示踪剂用于胰腺癌PET显像的临床转化
本研究开发了68Ga标记的整合素αvβ6靶向环肽(68Ga-cycratide),在BxPC-3胰腺癌小鼠模型中其肿瘤摄取显著高于线性肽(68Ga-linear-pep),部分归因于体内稳定性明显改善。5名健康志愿者(2女3男)注射后行全身PET/CT,计算了生物分布与剂量学,耐受良好;2例胰腺癌患者的初步PET/CT显示其诊断显像和术后肿瘤复发监测与18F-FDG相当。结论认为68Ga-cycratide具有良好的药代动力学和剂量学特征,有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。
要点
- 68Ga-cycratide在BxPC-3胰腺癌小鼠模型中肿瘤摄取显著高于线性肽68Ga-linear-pep。
- 5名健康志愿者(2女3男)注射68Ga-cycratide后全身PET/CT耐受良好,并计算了生物分布与剂量学。
- 2例胰腺癌患者初步PET/CT显示68Ga-cycratide诊断显像与术后复发监测与18F-FDG相当。
核心结论
- 68Ga-cycratide是一种整合素αvβ6特异性PET放射性示踪剂,具有良好药代动力学和良好剂量学特征。
- 作者认为68Ga-cycratide有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。
研究设计与样本
- 研究制备68Ga-cycratide,并在整合素αvβ6阳性BxPC-3人胰腺癌小鼠模型中与线性肽68Ga-linear-pep比较PET显像表现。
- 5名健康志愿者(2女3男)注射68Ga-cycratide后行全身PET/CT,计算生物分布与剂量学。
- 对2例胰腺癌患者行PET/CT显像,探讨68Ga-cycratide在胰腺癌诊断与治疗监测中的潜在作用。
主要发现
- 68Ga-cycratide在BxPC-3荷瘤小鼠中的肿瘤摄取显著高于68Ga-linear-pep,至少部分归因于体内稳定性明显改善。
- 68Ga-cycratide在原位小鼠模型中可灵敏检出胰腺癌病灶,且在全部健康志愿者中耐受良好。
- 胰腺癌患者初步PET/CT显示68Ga-cycratide诊断显像与术后肿瘤复发监测与18F-FDG相当。
临床怎么用
- 作者认为68Ga-cycratide有望为胰腺癌病灶检测和治疗反应监测提供有效的无创PET策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The overexpression of integrin αvβ6 in pancreatic cancer makes it a promising target for noninvasive PET imaging. However, currently, most integrin αvβ6-targeting radiotracers are based on linear peptides, which are quickly degraded in the serum by proteinases. Herein, we aimed to develop and assess a 68Ga-labeled integrin αvβ6-targeting cyclic peptide (68Ga-cycratide) for PET imaging of pancreatic cancer. Methods:68Ga-cycratide was prepared, and its PET imaging profile was compared with that of the linear peptide (68Ga-linear-pep) in an integrin αvβ6-positive BxPC-3 human pancreatic cancer mouse model. Five healthy volunteers (2 women and 3 men) underwent whole-body PET/CT imaging after injection of 68Ga-cycratide, and biodistribution and dosimetry were calculated. PET/CT imaging of 2 patients was performed to investigate the potential role of 68Ga-cycratide in pancreatic cancer diagnosis and treatment monitoring. Results:68Ga-cycratide exhibited significantly higher tumor uptake than did 68Ga-linear-pep in BxPC-3 tumor-bearing mice, owing-at least in part-to markedly improved in vivo stability. 68Ga-cycratide could sensitively detect the pancreatic cancer lesions in an orthotopic mouse model and was well tolerated in all healthy volunteers. Preliminary PET/CT imaging in patients with pancreatic cancer demonstrated that 68Ga-cycratide was comparable to 18F-FDG for diagnostic imaging and postsurgery tumor relapse monitoring. Conclusion:68Ga-cycratide is an integrin αvβ6-specific PET radiotracer with favorable pharmacokinetics and a favorable dosimetry profile. 68Ga-cycratide is expected to provide an effective noninvasive PET strategy for pancreatic cancer lesion detection and therapy response monitoring.
引用
- Feng X, Wang Y, Lu D, et al. Clinical Translation of a 68Ga-Labeled Integrin αvβ6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer. J Nucl Med. 2020. PMID: 32086242. doi:10.2967/jnumed.119.237347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。